|
|
Blood, Vol. 108, Issue 3, 870-877, August 1, 2006
Targeting self-antigens through allogeneic TCR gene transfer
Blood de Witte et al.
108: 870
Supplemental materials for: de Witte et al, Vol 108, Issue 3, 870-877
Files in this Data Supplement:
- Table S1. Pathology after OT-I transduced T-cell transfer in partially MHC-mismatched recipients (PDF, 13.8 KB)
- Table S2. Pathology after F5 transduced T-cell transfer in partially MHC-mismatched recipients (PDF, 10.9 KB)
- Table S3. Pathology after B6 BMT into Balb.B recipients (PDF, 9.84 KB)
- Figure S1. Tolerance in RIP-OVAhi mice (JPG, 48.4 KB)
-
(A) Flow cytometric analysis of blood samples of inflova-infected B6 (left) or RIP-OVAhi mice (right) at day 8 after infection.
(B) Immune responses toward the OVA257-264 epitope (left) or PR366-374 epitope (right) at day 8 after inflova infection in B6 mice (open circles) or RIP-OVAhi mice (filled circles). Circles represent individual mice; bars, averages.
- Figure S2. Analysis of OT-I transduced T cells prior to transduction (JPG, 84.4 KB)
-
Flow cytometric analysis of mock (left) or OT-I (right) transduced T cells prior to adoptive transfer. The number in the right upper corner of each dot plot reflects the percentage of V 2, V 5 double-positive cells within the CD8+ population. OT-I transduction efficiency in this experiment was 21%, and to transfer 1 × 105 OT-I+ CD8+ T cells, 4.8 × 105 T cells were infused. Within the different experiments in the RIP-OVAhi mice, OT-I transduction efficiencies varied between 15% and 50%.
- Figure S3. Lack of immunogenicity of B16-OVA tumors in RIP-OVAhi mice (JPG, 64.4 KB)
-
(A) RIP-OVAhi mice (left) and B6 mice (right) were challenged with 1 × 105 B16-OVA (top) or B16 cells (bottom) subcutaneously, followed by vaccination with rVV-OVA at the same day. Tumor growth was measured 3 times a week, starting at day 4 after inoculation. Lines represent growth curves in individual mice.
(B) Survival curve: Mice were killed when the average tumor diameter exceeded 12.5 mm.
- Figure S4. Antigen-driven expansion of OT-I transduced T cells in partially MHC-mismatched recipients (JPG, 53.3 KB)
-
Analysis of blood cells from B6*B10.BR (A), B6*Balb/C (B), and B6*FvB (C) mice that received no modified T cells (left) or 1 × 105 OT-I TCR-transduced T cells (right) followed by inflova infection. Transduction efficiencies were 18.6% (A), 9.4% (B), and 13.3% (C) of the CD8+ cells in the various experiments. Blood was sampled 5 to 14 days after infection and stained with FITC—anti-V5.1, PE—anti-V2, and APC—anti-CD8. Circles represent individual mice; bars, averages.
- Figure S5. Antigen-driven expansion of F5 TCR-transduced T cells in partially MHC-mismatched recipients (JPG, 53.5 KB)
-
Analysis of blood cells from B6*B10.BR (A), B6*Balb/C (B), and B6*FvB (C) mice that received no modified T cells (left) or 1 × 105 F5 TCR-transduced T cells (right) followed by influenza A/NT/60/68 infection. Transduction efficiencies were 23.8% (A), 17.9% (B), and 10.2 % (C) of the CD8+ cells Blood was sampled 5 to 14 days after infection and stained with FITC—anti-V11, PE—anti-V-pool, and APC—anti-CD8. Squares represent individual mice; bars, averages.
|
|
